Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kyungsuk Jung"'
Publikováno v:
Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-12 (2022)
Abstract Background Advanced understanding of tumor biology has recently revealed the complexity of cancer genetics, intra/inter-tumor heterogeneity, and diverse mechanisms of resistance to cancer treatment. In turn, there has been a growing interest
Externí odkaz:
https://doaj.org/article/fad74c87b34740e1b12cc0c7dcf4dc9f
Publikováno v:
The Korean Journal of Internal Medicine, Vol 35, Iss 5, Pp 1031-1044 (2020)
Squamous cell carcinoma of head and neck (SCCHN) is a group of cancer arising from mucosal surfaces of the head and neck. Optimal management of SCCHN requires a multidisciplinary team of surgical oncologists, radiation oncologists, medical oncologist
Externí odkaz:
https://doaj.org/article/8b06a06bc6bb4bb681a6505d4edaf941
Publikováno v:
Epidemiology and Health, Vol 40 (2018)
OBJECTIVES We investigated whether androgen deprivation therapy (ADT) in prostate cancer patients was associated with a decreased risk for second primary lung cancer in US veterans. METHODS Prostate cancer diagnoses in the US Veterans Affairs Cancer
Externí odkaz:
https://doaj.org/article/9c491925de21413fbc7b4e4c9dfa84b1
Publikováno v:
The Korean Journal of Internal Medicine
The Korean journal of internal medicine, vol 35, iss 5
The Korean Journal of Internal Medicine, Vol 35, Iss 5, Pp 1031-1044 (2020)
The Korean journal of internal medicine, vol 35, iss 5
The Korean Journal of Internal Medicine, Vol 35, Iss 5, Pp 1031-1044 (2020)
Squamous cell carcinoma of head and neck (SCCHN) is a group of cancer arising from mucosal surfaces of the head and neck. Optimal management of SCCHN requires a multidisciplinary team of surgical oncologists, radiation oncologists, medical oncologist
Autor:
Eric A. Gehrie, Ruchika Goel, Calvin Abro, Ashwin Gupta, Aaron A.R. Tobian, Michael B. Streiff, Clifford Takemoto, Kyungsuk Jung, Jonathan R Day, Evan M. Bloch
Publikováno v:
Blood. 136:39-40
Introduction Venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) is a cause of significant morbidity and mortality. Over the last decade, there has been an increase in awareness and major advances in early diagnosis
Autor:
Ruchika Goel, Ashwin Gupta, Jonathan R Day, Clifford Takemoto, Kyungsuk Jung, Calvin Abro, Lakshmanan Krishnamurti
Publikováno v:
Blood. 136:30-31
Introduction: Comprehensive management for patients with hemophilia has drastically improved outcomes, quality of care, and longevity. Because of increases in life span, patients with hemophilia may be at risk for other chronic conditions including c
Autor:
Eric A. Ross, Mark Andrake, Namrata Vijayvergia, Roland L. Dunbrack, Jeffrey Swensen, Kyungsuk Jung, Elena Shagisultanova, Qifang Xu, Joanne Xiu, Wafik S. El-Deiry, Avital Lev, Safoora Deihimi, Michael Slifker, Zoran Gatalica
Publikováno v:
Oncotarget
// Safoora Deihimi 1,2,3,7 , Avital Lev 1,2,3 , Michael Slifker 4 , Elena Shagisultanova 3,9 , Qifang Xu 2 , Kyungsuk Jung 5 , Namrata Vijayvergia 3 , Eric A. Ross 4,6 , Joanne Xiu 8 , Jeffrey Swensen 8 , Zoran Gatalica 8 , Mark Andrake 2 , Roland L.
Publikováno v:
Journal of Institute of Control, Robotics and Systems. 22:147-152
Publikováno v:
Cancers of the head & neck, vol 3, iss 1
Cancers of the Head & Neck, Vol 3, Iss 1, Pp 1-13 (2018)
Cancers of the Head & Neck
Cancers of the Head & Neck, Vol 3, Iss 1, Pp 1-13 (2018)
Cancers of the Head & Neck
The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents. At the same time, there has been a constant need for individually tai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d19090b9ab6267e37bfae9833027d466
https://escholarship.org/uc/item/695612kp
https://escholarship.org/uc/item/695612kp
Publikováno v:
BMC Nephrology
Background Immune checkpoint inhibitors are changing the landscape of oncology treatment as they are significantly improving treatment for multiple malignancies. Nivolumab, an anti-programmed death 1 antibody, is a US Food and Drug Administration-app